Subscriber login:
Remember me
IPD's Access Hub subscription is our payer and provider resource offering limited distribution network tracking, clinical criteria and formulary coverage information, clinical guidelines, therapy cost analytics, nonessential drug lists, biomarker test tracking, Medicaid meetings, and more.
Limited Distribution Drug Network Tracking
Stay on top of limited distribution drugs and their networks as the specialty drug landscape continues to expand. Until now, payers and providers have struggled to monitor shifting limited distribution networks, making it harder to provide these critical medicines to patients.
IPD’s limited distribution coverage is designed to centralize fragmented information on these networks to help organizations supply these drugs as efficiently and effectively as possible.
Therapy Cost Analytics
Dive deep into current and historical drug costs, evaluating entire disease classes, manufacturer portfolios, and individual drugs, to spot trends and monitor changes in the marketplace.
​
Using efficient dashboards, identify increases or decreases in costs, stay on top of new brand approvals, make better predictions about future marketplace conditions, compare competitors in various classes, and analyze specific groups of drugs.
Formulary Coverage Across Leading Insurers
Improve your current market visibility with insight into how national and regional payers are managing their formularies, including in-depth status and restriction information for specific drugs, disease classes, and manufacturer portfolios.
​
By normalizing disparate data from a set of leading formularies, our clinical research team makes it easy to compare across plans, spot trends, and identify best practices.
Clinical Criteria Benchmarking
View clinical criteria across leading plans in just a few clicks, including every step that plans are using to manage a specific therapy.
​
Collected from six major national plans, IPD’s clinical criteria and step therapy information provide an efficient way to benchmark your criteria against others or serve as a baseline for new step therapy strategies.
Patient Financial Assistance
Quickly understand how patients can mitigate out-of-pocket costs with up-to-date information covering manufacturer copay programs, free trials, patient assistance programs, and bridge programs.
With patient financial assistance information across disease states, therapeutic areas, companies, and drugs, you can easily pinpoint benefit design opportunities and pitfalls based on program availability.
Clinical Guidelines Library
Access an unparalleled Clinical Guidelines Library, providing an efficient way to find and track over 750 relevant, up-to-date professional society guidelines (including pharmacoeconomics, clinical guidelines, and clinical reviews) all in one place.
Utilizing our comprehensive therapeutic area and disease state searches, ensure your drug policies are always based on the most recent clinical guidelines.
Nonessential Drugs & PBM Exclusions​
Identify and avoid use of high-cost products that offer little to no additional safety or efficacy benefits compared to lower-cost alternatives with IPD's Nonessential Drug List, developed by our Executive Clinical Pharmacy team.
In addition, PBM Exclusion Lists from ESI, OptumRx, and CVS are displayed for easy comparison.
Biomarker Test Tracking
Evaluate pricing, payer coverage, access, and patient assistance programs for companion diagnostic tests used to determine the need for cutting-edge therapies.
Utilizing drug, disease state, therapeutic area, and biomarker views, identify
cost-effective companion diagnostics, patient assistance programs, laboratory patient access, and test manufacturers.
Medicaid Meetings
Stay ahead of all state Medicaid preferred drug list meetings in which formulary decisions are made, with meeting frequency, dates, agendas, outcomes, and public comments.
In addition, see indexed drugs, disease states, indications, mechanisms of action, and related topics in each agenda and easily pinpoint which meetings to attend or follow up on after decisions have been made.